Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GW-1100 is a selective antagonist of GPR40 (pIC50: 6.9). GW1100 also plays the role of a GPR40 inverse agonist.
产品描述 | GW-1100 is a selective antagonist of GPR40 (pIC50: 6.9). GW1100 also plays the role of a GPR40 inverse agonist. |
靶点活性 | FFA1/GPR40:(pic50)6.9 |
体外活性 | GW-1100 (1 μM) produces a significant rightward shift in the concentration-response curve to GW9508 (pEC50=7.17±0.08 in the absence and pEC50=6.79±0.09 in the presence of 1 μM GW-1100; P<0.05; n=3). At concentrations of GW-1100 (3 μM and higher) shows a significant decrease in the maximal response is observed with a continuing rightward shift in the pEC50 response[2]. CHO-K1/bFFAR1 cells are incubated for 15 min with 10 μM GW1100 or vehicle (0.1% DMSO) and then stimulated with vehicle, oleic acid, linoleic acid or GW9508. GW-1100 significantly reduces the increase in intracellular calcium induced by 300 μM oleic acid (AUC(60-150 s), p<0.05), 100 μM linoleic acid (AUC(60-150 s), p<0.05) and 10 μM GW9508 (AUC(60-150 s), p<0.05)[3]. GW-1100 dose dependently suppresses GPR40-mediated Ca2+ elevations stimulated by GW9508 and linoleic acid (pIC50: 5.99±0.03 and 5.99±0.06, respectively). GW-1100 causes FFAR1 ligand-induced intracellular calcium in CHO-K1/bFFAR1 cells and neutrophils. |
体内活性 | These effects are inhibited by intracerebroventricular pretreatment with GW-1100 (10 μg), a GPR40 antagonist. The intracerebroventricular injection of DHA (50 μg) and GW9508 (1.0 μg) are a GPR40-selective agonist. This obviously decreases mechanical allodynia and thermal hyperalgesia on day 7, but not on day 1, after CFA injection[4]. |
分子量 | 520.58 |
分子式 | C27H25FN4O4S |
CAS No. | 306974-70-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (96.05 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9209 mL | 9.6047 mL | 19.2093 mL | 48.0234 mL |
5 mM | 0.3842 mL | 1.9209 mL | 3.8419 mL | 9.6047 mL | |
10 mM | 0.1921 mL | 0.9605 mL | 1.9209 mL | 4.8023 mL | |
20 mM | 0.096 mL | 0.4802 mL | 0.9605 mL | 2.4012 mL | |
50 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.9605 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GW-1100 306974-70-9 Endocrinology/Hormones GPCR/G Protein GPR GW1100 GW 1100 Inhibitor inhibitor inhibit